ScholarLens Back to search
2004•Zhongguo jihua mianyiRequires access

Study on Safety and Immunogenicity of Healive Inactivated Hepatitis A Vaccine Used among Children

LV Zuo-zhi

Open publisher page 2 citations

Abstract

To study the safety and immunogenicity of the Healive inactivated hepatitis A vaccine (HepAV) used among children 91 HAV antibody negative susceptible healthy children aged 2 to 15 were selected and vaccinated 250u/dose following the 0,6 months schedule The local and the systemic adverse effects were observed after vaccination,and the seroconvertion rate and geometric mean titers (GMT) of HAV antibodies were tested one month after full dose vaccination The results showed there were no severe adverse events occurred after the 1st and 2nd dose HepAV vaccination,only some slight and temporary local and systemic reactions 8～72 hs after vaccination The seroconvertion rate of HAV antibody was 100% one month after full dose vaccination,while the anti-HAV GMT was 14407mIU/ml It was concluded that the Healive inactivated HepAV has satisfactory safety and immunogenictity used among children High titer antibody can be attained following 0,6 months schedule

About this research paper

What this paper is about

To study the safety and immunogenicity of the Healive inactivated hepatitis A vaccine (HepAV) used among children 91 HAV antibody negative susceptible healthy children aged 2 to 15 were selected and vaccinated 250u/dose following the 0,6 months schedule The local and the systemic adverse effects were observed after vaccination,and the seroconvertion rate and geometric mean titers (GMT) of HAV antibodies were tested one month after full dose vaccination The results showed there were no severe adverse events occurred after the 1st and 2nd dose HepAV vaccination,only some slight and temporary local and systemic reactions 8～72 hs after vaccination The seroconvertion rate of HAV antibody was 100% one month after full dose vaccination,while the anti-HAV GMT was 14407mIU/ml It was concluded that the Healive inactivated HepAV has satisfactory safety and immunogenictity used among children High titer antibody can be attained following 0,6 months schedule

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

To study the safety and immunogenicity of the Healive inactivated hepatitis A vaccine (HepAV) used among children 91 HAV antibody negative susceptible healthy children aged 2 to 15 were selected and vaccinated 250u/dose following the 0,6 months schedule The local and the systemic adverse effects were observed after vaccination,and the seroconvertion rate and geometric mean titers (GMT) of HAV antibodies were tested one month after full dose vaccination The results showed there were no severe adverse events occurred after the 1st and 2nd dose HepAV vaccination,only some slight and temporary local and systemic reactions 8～72 hs after vaccination The seroconvertion rate of HAV antibody was 100% one month after full dose vaccination,while the anti-HAV GMT was 14407mIU/ml It was concluded that the Healive inactivated HepAV has satisfactory safety and immunogenictity used among children High titer antibody can be attained following 0,6 months schedule

Key concepts: Medicine, Immunogenicity, Hepatitis A vaccine, Vaccination, Adverse effect, Titer, Vaccination schedule, Hepatitis A

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Study on Safety and Immunogenicity of Healive Inactivated Hepatitis A Vaccine Used among Children — Research Paper | ScholarLens